Anti-natural killer group 2D CAR-T cell therapy - Yake Biotechnology
Alternative Names: NKG2D CAR-T cells injectionLatest Information Update: 31 Oct 2021
At a glance
- Originator Yake Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 08 Dec 2020 Preclinical trials in Acute myeloid leukaemia in China (IV) prior to December 2020 (Yake Biotechnology pipeline, December 2020)
- 08 Dec 2020 Zhejiang University in collaboration with Yake Biotechnology plans a phase I trial for Acute Myeloid Leukemia (Second-line therapy or greater, In children, In adults, In the elderly) in China (IV, Infusion) in January 2021 (NCT04658004)